Overview

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms of local disease control (progression-free) rate at 2 years.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Cisplatin
Gefitinib